NEO NeoGenomics, Inc.
Healthcare$9.27+0.43%ClosedMarket Cap: $241.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.29
P/S
0.32
EV/EBITDA
-15.29
DCF Value
$-130.77
FCF Yield
-2.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
42.1%
Operating Margin
-13.9%
Net Margin
-13.3%
ROE
-11.8%
ROA
-7.4%
ROIC
-8.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $186.7M | 43.3% | $-18.2M | $-17.1M | $— | — |
| Q4 null | $190.2M | 39.8% | $-11.1M | $-9.9M | $— | — |
| FY null | $727.3M | 38.8% | $-66.1M | $-108.0M | $— | — |
| Q3 null | $187.8M | 42.8% | $-27.0M | $-27.1M | $— | — |
| Q2 null | $181.3M | 42.6% | $-47.6M | $-45.1M | $— | — |
| Q1 null | $168.0M | 43.6% | $-27.8M | $-25.9M | $— | — |
| Q4 null | $172.0M | 44.9% | $-18.4M | $-15.3M | $— | — |
| FY null | $660.6M | 43.9% | $-92.1M | $-78.7M | $— | — |
| Q3 null | $167.8M | 44.6% | $-21.2M | $-17.7M | $— | — |
| Q2 null | $164.5M | 44.1% | $-21.9M | $-18.6M | $— | — |
| Q1 null | $156.2M | 41.9% | $-30.6M | $-27.1M | $— | — |
| Q4 2023 | $155.6M | 43.5% | $-18.6M | $-14.3M | $-0.55 | — |